Inflammatory bowel disease and the risk of fracture

被引:183
作者
Van Staa, TP
Cooper, C
Brusse, LS
Leufkens, H
Javaid, MK
Arden, NK [1 ]
机构
[1] Univ Southampton, Southampton Gen Hosp, Med Res Council, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England
[2] Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[3] Procter & Gamble Co, Pharmaceut, Staines, England
关键词
D O I
10.1053/j.gastro.2003.09.027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Although patients with inflammatory bowel disease (IBD) have reduced bone mass, there is controversy whether there is an increased risk of fracture. This study examines the risk of fracture and its predictors in patients with IBD. Methods: In a primary care-based nested case-control study, 231,778 fracture cases and 231,778 age- and sex-matched controls were recruited. A history of IBD was assessed from medical records. Results: The prevalence of IBD was 156 and 282 per 100,000 for Crohn's disease (CD) and ulcerative colitis (UC), respectively. Patients with IBD had an increased risk of vertebral fracture (odds ratio [OR], 1.72; 95% confidence interval [CI], 11.3-2.61) and hip fracture (OR, 1.59; 95% CI, 1.14-2.23). The risk of hip fracture was greater in patients with CD (OR, 1.86; 95% CI, 1.08-3.21) compared with UC (OR, 140; 95% CI, 0.92-2.13). Disease severity, assessed by the number of symptoms, predicted fracture even after adjusting for corticosteroid use (OR, 1.46; 95% CI, 1.04-2.04). Only 13% of patients with IBD who had already sustained a fracture were on any form of antifracture treatment. Conclusions: Patients with IBD have a higher risk of fracture due to both disease activity and use of oral corticosteroids. However, few of these patients are receiving optimal bone-sparing therapy, highlighting the importance of increasing awareness of osteoporosis in those managing these patients.
引用
收藏
页码:1591 / 1597
页数:7
相关论文
共 41 条
[1]   METABOLIC BONE ASSESSMENT IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
ABITBOL, V ;
ROUX, C ;
CHAUSSADE, S ;
GUILLEMANT, S ;
KOLTA, S ;
DOUGADOS, M ;
COUTURIER, D ;
AMOR, B .
GASTROENTEROLOGY, 1995, 108 (02) :417-422
[2]  
American Gastroenterological Association, 2003, GASTROENTEROLOGY, V124, P791, DOI DOI 10.1053/GAST.2003
[3]  
[Anonymous], 1994, Pharmacoepidemiology) and Drug Safety
[4]   Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis [J].
Ardizzone, S ;
Bollani, S ;
Bettica, P ;
Bevilacqua, M ;
Molteni, P ;
Porro, GB .
JOURNAL OF INTERNAL MEDICINE, 2000, 247 (01) :63-70
[5]   The incidence of fracture among patients with inflammatory dowel disease - A population-based cohort study [J].
Bernstein, CN ;
Blanchard, JF ;
Leslie, W ;
Wajda, A ;
Yu, BN .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (10) :795-799
[6]  
BERNSTEIN CN, 1995, J BONE MINER RES, V10, P250
[7]  
Bischoff SC, 1997, AM J GASTROENTEROL, V92, P1157
[8]   Reduced bone density in patients with inflammatory bowel disease [J].
Bjarnason, I ;
Macpherson, A ;
Mackintosh, C ;
BuxtonThomas, M ;
Forgacs, I ;
Moniz, C .
GUT, 1997, 40 (02) :228-233
[9]   LONGITUDINAL-STUDY OF CORTICAL BONE LOSS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
CLEMENTS, D ;
MOTLEY, RJ ;
EVANS, WD ;
HARRIES, AD ;
RHODES, J ;
COLES, RJ ;
COMPSTON, JE .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (12) :1055-1060
[10]   OSTEOPOROSIS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
COMPSTON, JE ;
JUDD, D ;
CRAWLEY, EO ;
EVANS, WD ;
EVANS, C ;
CHURCH, HA ;
REID, EM ;
RHODES, J .
GUT, 1987, 28 (04) :410-415